June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Aflibercept for Diabetic Macular edema In real-life practice in GREece: Three-year outcomes of the ADMIRE study
Author Affiliations & Notes
  • Eirini Chatziralli
    2nd Department of Ophthalmology, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Attica, Greece
  • Dimitrios Kazantzis
    2nd Department of Ophthalmology, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Attica, Greece
  • Eleni Dimitriou
    2nd Department of Ophthalmology, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Attica, Greece
  • George Theodossiadis
    2nd Department of Ophthalmology, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Attica, Greece
  • Panagiotis Theodossiadis
    2nd Department of Ophthalmology, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Attica, Greece
  • Footnotes
    Commercial Relationships   Eirini Chatziralli None; Dimitrios Kazantzis None; Eleni Dimitriou None; George Theodossiadis None; Panagiotis Theodossiadis None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, OD76. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eirini Chatziralli, Dimitrios Kazantzis, Eleni Dimitriou, George Theodossiadis, Panagiotis Theodossiadis; Aflibercept for Diabetic Macular edema In real-life practice in GREece: Three-year outcomes of the ADMIRE study. Invest. Ophthalmol. Vis. Sci. 2023;64(8):OD76.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy and safety of intravitreal aflibercept injections for diabetic macular edema (DME) treatment in a tertiary referral center in Greece.

Methods : ADMIRE was a prospective, observational cohort study of patients with DME. Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to month 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.

Results : Participants in the study were 94 patients with DME, 70 treatment-naïve and 24 previously treated with ranibizumab. At month 36 of the follow-up period, the mean change (SD) in BCVA was +7.4 ETDRS letters compared to baseline (p<0.001). The mean change in BCVA in treatment-naïve patients was +8.9 letters and differed significantly compared to previously treated patients (+5.9, p=0.041). In addition, patients who received a loading dose of 5 monthly injections at the initiation of treatment provided better VA outcomes (+11.4 vs. +6.1 letters, p<0.001). Accordingly, the mean CRT at month 36 was significantly decreased compared to baseline (479.2±68.3 μm vs. 369.6±72.8 μm, p<0.001). Overall, the mean number of injections was 7.2 at month 12, 10.7 at month 24 (mean 3.3 injections between months 12 and 24) and 13.4 at month 36 (mean 2.9 injections between months 24 and 36). Safety analysis showed that 28.7%. of patients reported ocular adverse events during the 36-month study period, which were mild and not sight-threatening, such as subconjunctival hemorrhage, cataract development, vitreous floaters, anterior uveitis, corneal abrasion and intraocular pressure elevation. No patient reported non-ocular adverse events. .

Conclusions : Intravitreal aflibercept was found to be safe and effective for the treatment of DME in real-life in a Greek population. Treatment naïve patients and those who received a loading dose of 5 consecutive monthly injections at initiation of treatment exhibited better outcomes compared to patients who were previously treated with intravitreal ranibizumab and to those who did not follow the loading dose protocol, suggesting that early and effective treatment may prevent vision loss.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×